108 related articles for article (PubMed ID: 33885357)
21. [Analysis of risk factors of axillary lymph node metastasis and prognosis in T1 breast cancer: a large-scale retrospective study based on the SEER database].
Wang WY; Meng XZ; Li N; Zeng HM; Liu JX; Feng KX; Wang PL; Wang X
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2152-2158. PubMed ID: 34275251
[No Abstract] [Full Text] [Related]
22. Investigation of prognostic value of polymorphisms within estrogen metabolizing genes in Lithuanian breast cancer patients.
Savukaitytė A; Ugenskienė R; Jankauskaitė R; Čereškevičius D; Šepetauskienė E; Juozaitytė E
BMC Med Genet; 2015 Feb; 16():2. PubMed ID: 25648141
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
[TBL] [Abstract][Full Text] [Related]
24. Effects of HER2 genetic polymorphisms on its protein expression in breast cancer.
Su Y; Jiang Y; Sun S; Yin H; Shan M; Tao W; Ge X; Pang D
Cancer Epidemiol; 2015 Dec; 39(6):1123-7. PubMed ID: 26323365
[TBL] [Abstract][Full Text] [Related]
25. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
[TBL] [Abstract][Full Text] [Related]
26. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
27. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
28. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
29. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
30. Analysis of clinicopathological factors associated with bone metastasis in breast cancer.
Chen J; Zhu S; Xie XZ; Guo SF; Tong LQ; Zhou S; Zhao M; Xianyu ZQ; Zhu XH; Xiong W
J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):122-125. PubMed ID: 23392720
[TBL] [Abstract][Full Text] [Related]
31. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
32. Relationships between SNPs and prognosis of breast cancer and pathogenic mechanism.
He Y; Liu H; Chen Q; Shao Y; Luo S
Mol Genet Genomic Med; 2019 Sep; 7(9):e871. PubMed ID: 31317673
[TBL] [Abstract][Full Text] [Related]
33. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
34. The impact of renin-angiotensin system, angiotensin І converting enzyme (insertion/deletion), and angiotensin ІІ type 1 receptor (A1166C) polymorphisms on breast cancer survival in Iran.
Namazi S; Daneshian A; Mohammadianpanah M; Jafari P; Ardeshir-Rouhani-Fard S; Nasirabadi S
Gene; 2013 Dec; 532(1):125-31. PubMed ID: 24055489
[TBL] [Abstract][Full Text] [Related]
35. Association of interleukin-10 gene variation with breast cancer prognosis.
Gerger A; Renner W; Langsenlehner T; Hofmann G; Knechtel G; Szkandera J; Samonigg H; Krippl P; Langsenlehner U
Breast Cancer Res Treat; 2010 Feb; 119(3):701-5. PubMed ID: 19437115
[TBL] [Abstract][Full Text] [Related]
36. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
37. KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes.
Hartikainen JM; Tengström M; Winqvist R; Jukkola-Vuorinen A; Pylkäs K; Kosma VM; Soini Y; Mannermaa A
Clin Cancer Res; 2015 Apr; 21(7):1591-601. PubMed ID: 25589623
[TBL] [Abstract][Full Text] [Related]
38. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
39. MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer.
Choschzick M; Heilenkötter U; Lebeau A; Jaenicke F; Terracciano L; Bokemeyer C; Sauter G; Simon R
Cancer Biomark; 2010-2011; 8(2):53-60. PubMed ID: 21896991
[TBL] [Abstract][Full Text] [Related]
40. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]